Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 181147-94-4 | MDL No. : | MFCD11042212 |
Formula : | C9H5BrFN | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | CZZGLPOYHNAIBA-UHFFFAOYSA-N |
M.W : | 226.05 | Pubchem ID : | 71435631 |
Synonyms : |
|
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 10 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 49.4 |
TPSA : | 12.89 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.33 cm/s |
Log Po/w (iLOGP) : | 2.3 |
Log Po/w (XLOGP3) : | 3.31 |
Log Po/w (WLOGP) : | 3.56 |
Log Po/w (MLOGP) : | 2.98 |
Log Po/w (SILICOS-IT) : | 3.54 |
Consensus Log Po/w : | 3.14 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -3.94 |
Solubility : | 0.0257 mg/ml ; 0.000114 mol/l |
Class : | Soluble |
Log S (Ali) : | -3.26 |
Solubility : | 0.125 mg/ml ; 0.000554 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -4.84 |
Solubility : | 0.00327 mg/ml ; 0.0000145 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.94 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P233-P260-P261-P264-P271-P280-P302+P352-P304-P304+P340-P305+P351+P338-P312-P321-P332+P313-P337+P313-P340-P362-P403-P403+P233-P405-P501 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
a3) 2-(7-Fluoro-quinolin-2-yl)-ethylamine According to route a) starting from <strong>[181147-94-4]2-bromo-7-fluoro-quinoline</strong> |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
[00194] To a solution of <strong>[181147-94-4]7-fluoro-2-bromoquinoline</strong> (54.1 mg) in THF (2 mL) was added BuLi (1.6 M, 0.25 mL) at -78C. After 5 min, a solution of phenyl ketone (60.0 mg) in THF (1 mL) was added at-78C. The reaction was immediately allowed to warm up to room temperature and stirred for 30 min. The reaction mixture was quenched with water (30 mL). The whole was extracted with AcOEt (30 mL x 3). Organic layer was washed with brine (30 mL) and dried over Na2S04. The solvent was removed under a reduced pressure to give the crude product. The crude product was treated with TFA to cleave the Boc group. The crude product was purified by a silica gel column chromatography (hexane: EtOAc, 7: 1 to 3:1) to give tert-butyl 4-benzoyl-6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazole-l- carboxylate. [00195] C26H27N305. MS. m/z 509.2 (M+l). |